Most Read Articles
01 Jun 2015
New drug applications approved by US FDA as of 15 – 31 May 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
10 Oct 2016
Use of dipeptidyl peptidase-4 (DPP-4) inhibitors may reduce the risk of mortality and the combination of myocardial infarction and ischaemic stroke in type 2 diabetes (T2D), without increasing the risk of hospitalisation for heart failure even in T2D patients with pre-existing HF, a nationwide cohort study from Taiwan suggests.

Product Highlight - BLACKMORES ESSENTIAL LIVO

01 Oct 2015
BLACKMORES ESSENTIAL LIVO – Phosphatidylcholine, Zinc and Chromium Capsules
  • The support of normal cholesterol, fat metabolism and liver health
  • Improved digestive assistance via the support of fat, carbohydrate and protein metabolism
  • Liver detoxification and antioxidant support
  • Maintenance of normal glucose metabolism
References:
1. Canty D and Zeisel S, Lecithin and Choline in Human Health and Disease, Nutrition Reviews, 1994; 52 (10): 327-339
2.
Health Canada. Choline: Monograph, .September, 2009. http://webprod.hc-sc.gc.ca/nhpid-bdipsn/monoReq.do?id=195&lang=eng (accessed 18th January 2012)
3. Hendler SS. PDR for nutritional supplements 2nd edition. Montvale, Physicians desk reference, 2008
4.
NHMRC, Chromium, Nutrient Reference Values for Australia and New Zealand, Commonwealth of Australia 2006; 235-240
5.
http://webprod.hc-sc.gc.ca/nhpid-bdipsn/monoReq.do?id=64&lang=eng Health Canada Monograph (accessed 23/10/12)

Further information is available in Section 1g and 31b, New In This Issue and mims.com.
Full prescribing information is available upon request.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Jun 2015
New drug applications approved by US FDA as of 15 – 31 May 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
10 Oct 2016
Use of dipeptidyl peptidase-4 (DPP-4) inhibitors may reduce the risk of mortality and the combination of myocardial infarction and ischaemic stroke in type 2 diabetes (T2D), without increasing the risk of hospitalisation for heart failure even in T2D patients with pre-existing HF, a nationwide cohort study from Taiwan suggests.